Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 plus carboplatin as first-line therapy in advanced ovarian cancer
ChiCTR2500096933Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival (PFS). Planned start Feb 2025; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500096933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096933.